1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,680 | 2,865 | 21:45 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2024 | 45 | GlobeNewswire (Europe) | October-December 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,002 thousand (-54,513)Earnings per share before dilution amounted to SEK -2.36 (-1.85)Cash flow... ► Artikel lesen | |
| 20.01. | XSpray Pharma AB: Xspray Pharma reports strong interim data for product candidate XS003 - confirms plan to apply for market approval in H1 2025 | 64 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today presents interim data from a food interaction study with the nilotinib product candidate (XS003). The results confirm the benefits of the company's patented HyNap technology... ► Artikel lesen | |
| 14.11.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Xspray Pharma AB | 295 | GlobeNewswire | With effect from November 15, 2024, the subscription rights of Xspray Pharma
AB will be traded on the list for Equity rights. Trading will continue up until
and including November 26, 2024.
Instrument:... ► Artikel lesen | |
| 12.11.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.11.2024 | 2.207 | Xetra Newsboard | Das Instrument 3O41 BMG611881019 LIBERTY GLOBAL LTD CL.A EQUITY wird cum Kapitalmassnahme gehandelt am 12.11.2024 und ex Kapitalmassnahme am 13.11.2024 The instrument 3O41 BMG611881019 LIBERTY GLOBAL... ► Artikel lesen | |
| 06.11.24 | XSpray Pharma AB: Interim Report Third Quarter 2024 | 121 | GlobeNewswire (Europe) | July - September 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,272 thousand (-38,942)Earnings per share before dilution amounted to SEK -2.44 (-1.59)Cash flow... ► Artikel lesen | |
| 06.11.24 | XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 135 million and raises a loan of SEK 100 million | 170 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 19.09.24 | Xspray Pharma AB: Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission | 298 | Business Wire | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap technology to develop enhanced cancer therapies, today announced significant progress... ► Artikel lesen | |
| 06.09.24 | Scientific Article in Leading Journal Endorses Xspray Pharma's HyNap Technology | 424 | Business Wire | A new scientific article, published in the US journal Clinical Pharmacology in Drug Development, shows how Xspray Pharma's HyNap technology improves the bioavailability and reduces variability of... ► Artikel lesen | |
| XSPRAY PHARMA Aktie jetzt für 0€ handeln | |||||
| 07.08.24 | XSpray Pharma AB: Interim Report Second Quarter 2024 | 141 | GlobeNewswire (Europe) | April-June 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -53,620 thousand (-51,402)Earnings per share before dilution amounted to SEK -1.64 (-2.27)Cash flow from... ► Artikel lesen | |
| 26.07.24 | XSpray Pharma AB: Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development | 452 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Dasynoc... ► Artikel lesen | |
| 09.07.24 | Xspray Pharma AB: Xspray Pharma's XS003 Study Shows Matching Bioavailability to Tasigna at More than a 50% Lower Dose | 370 | Business Wire | Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose.
Xspray Pharma AB (Stockholm/Nasdaq:... ► Artikel lesen | |
| 08.05.24 | XSpray Pharma AB: Interim Report First Quarter 2024 | 218 | GlobeNewswire (Europe) | January-March 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -67,781 thousand (-34,827)Earnings per share before dilution amounted to SEK -2.17 (-1.54)Cash flow from... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,135 | +1,25 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
| TEMPUS AI | 46,695 | -3,20 % | Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? | ||
| BIOAFFINITY TECHNOLOGIES | 1,050 | +281,82 % | RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 13,940 | -12,38 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 6,125 | +1,07 % | Evotec-Aktie: Crash auf 4 Euro voraus? Behält die Deutsche Bank Recht mit Ihrem Kursziel? | © Foto: Symbolbild von pina messina auf UnsplashKooperationen mit Pharma-Giganten, Hightech-Forschung und trotzdem bewegt sich die Evotec-Aktie nicht richtig nach oben. Die Deutsche Bank warnte vor... ► Artikel lesen | |
| BIONTECH | 84,90 | +2,97 % | EQS-News: CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im Rechtsstreit mit BioNTech SE
27.03.2025... ► Artikel lesen | |
| BEAM THERAPEUTICS | 17,610 | -9,90 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| BB BIOTECH | 31,900 | +0,31 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,065 | -4,16 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
| SPRINGWORKS THERAPEUTICS | 41,490 | -6,02 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| IMMUNOVANT | 15,210 | -10,95 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
| NUVALENT | 68,80 | -2,93 % | Nuvalent-Entwicklungschefin verkauft Aktien im Wert von 292.468 US-Dollar | ||
| SUMMIT THERAPEUTICS | 18,780 | -2,67 % | Cantor Fitzgerald maintains Overweight on Summit Therapeutics shares | ||
| KYMERA THERAPEUTICS | 24,970 | -8,84 % | Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.2% - Should You Sell? | ||
| GUBRA | 63,00 | +12,90 % | Gubra-Aktie +15%: Zeit fürs Comeback! | Die Gubra-Aktie ist in den letzten vier Wochen unter massiven Verkaufsdruck geraten und hat über ein Drittel ihres Wertes eingebüßt. Doch am Dienstagmorgen sendet das Papier des dänischen Biopharmaunternehmens... ► Artikel lesen |
XSPRAY PHARMA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +4,22 % bei einem Aktienkurs von 2,595 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XSPRAY PHARMA AB finden Sie auf Wallstreet Online.
